TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 24
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 DBMR TRIPOD DATA VALIDATION MODEL 31
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.6 MULTIVARIATE MODELLING 35
2.7 MARKET APPLICATION COVERAGE GRID 36
2.8 SOURCE LIFELINE CURVE 36
2.9 DBMR MARKET POSITION GRID 38
2.10 VENDOR SHARE ANALYSIS 39
2.11 SECONDARY SOURCES 40
2.12 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
3.1 PESTEL ANALYSIS 45
3.2 PORTER'S FIVE FORCES MODEL 46
3.3 INDUSTRIAL INSIGHTS: 47
3.4 PIPELINE ANALYSIS FOR NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET 49
3.5 EPIDEMIOLOGY 50
4 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS 51
4.1 UNITED STATES (U.S.) 51
4.1.1 ROLE OF FDA 51
4.1.2 ROLE OF CDC AND HCFA 51
4.2 EUROPEAN UNION (EU) 52
4.3 FRANCE 52
4.4 AUSTRALIA 52
4.5 SOUTH KOREA 52
5 MARKET OVERVIEW 53
5.1 DRIVERS 55
5.1.1 INCREASE IN THE NUMBER OF PATIENTS SUFFERING FROM PSYCHIATRIC AND DEPRESSION DISORDER 55
5.1.2 RISE IN HEALTHCARE EXPENDITURE 55
5.1.3 RISE IN DEMAND FOR PERSONALIZED AND PRECISION MEDICINE 56
5.2 RESTRAINTS 56
5.2.1 LACK OF SKILLED MEDICAL AND GENOMIC EXPERT 56
5.2.2 LACK OF STRONG CLINICAL EVIDENCE 57
5.2.3 HIGH COST ASSOCIATED WITH THE DIAGNOSIS 57
5.3 OPPORTUNITIES 57
5.3.1 RISING ADVANCEMENTS IN TECHNOLOGY 57
5.3.2 INCREASING NUMBER OF KEY PLAYERS IN MARKET 58
5.4 CHALLENGES 58
5.4.1 STRICT GOVERNMENT REGULATION ON NEW PRODUCTS AND INSTRUMENTS APPROVAL 58
5.4.2 DEARTH OF SKILLED PERSONNEL 59
6 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE 60
6.1 OVERVIEW 61
6.2 ANXIETY 64
6.3 DEPRESSION 64
6.4 MOOD DISORDERS 65
6.5 BIPOLAR DISORDERS 66
6.6 EATING DISORDERS 67
6.7 PSYCHOTIC DISORDERS 67
7 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT 69
7.1 OVERVIEW 70
7.2 CONSUMABLES 73
7.2.1 WHOLE GENOME SEQUENCING KITS 74
7.2.2 CHROMOSOMAL ARRAY BASED KITS 74
7.3 INSTRUMENTS 75
7.4 SOFTWARE AND SERVICES 75
8 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE 77
8.1 OVERVIEW 78
8.2 WHOLE GENOME SEQUENCING 81
8.2.1 EXOME SEQUENCING 82
8.2.1.1 SNP 83
8.2.1.2 CNV 83
8.2.1.3 RARE PTV MUTATION 83
8.2.1.4 ULTRA PTV MUTATION 83
8.2.1.5 OTHERS 83
8.2.2 KARYOTYPE 83
8.2.2.1 SNP 84
8.2.2.2 CNV 84
8.2.2.3 RARE PTV MUTATION 84
8.2.2.4 ULTRA PTV MUTATION 84
8.2.2.5 OTHERS 84
8.2.3 LOW COVERAGE WGS 84
8.2.3.1 SNP 85
8.2.3.2 CNV 85
8.2.3.3 RARE PTV MUTATION 85
8.2.3.4 ULTRA PTV MUTATION 85
8.2.3.5 OTHERS 85
8.2.4 DEEP COVERAGE WGS 85
8.2.4.1 SNP 86
8.2.4.2 CNV 86
8.2.4.3 RARE PTV MUTATION 86
8.2.4.4 ULTRA PTV MUTATION 86
8.2.4.5 OTHERS 86
8.2.5 MICROARRAY 86
8.2.5.1 SNP 87
8.2.5.2 CNV 87
8.2.5.3 RARE PTV MUTATION 87
8.2.5.4 ULTRA PTV MUTATION 87
8.2.5.5 OTHERS 87
8.2.6 OTHERS 87
8.3 CHROMOSOMAL ARRAY BASED TESTS 87
8.3.1 MICRODELETIONS 88
8.3.2 MICRO DUPLICATIONS 88
9 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE 89
9.1 OVERVIEW 90
9.2 CYP2C19 93
9.3 CYP2C9 AND VKORC1 93
9.4 CYP2D6 94
9.5 HLA-B 95
9.6 HTR2A/C 95
9.7 HLA-A 96
9.8 CYP3A4 97
9.9 SLC6A4 97
9.10 MTHFR 98
9.11 COMT 99
9.12 OTHERS 99
10 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE 101
10.1 OVERVIEW 102
10.2 ADULT 105
10.3 GERIATRIC 105
10.4 CHILD 106
11 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER 107
11.1 OVERVIEW 108
11.2 HOSPITAL AND CLINICS 111
11.2.1 DRUG EFFECTIVENESS 112
11.2.2 SIDE EFFECTS 112
11.2.3 DOSAGE 112
11.3 DIAGNOSTICS LABORATORIES 112
11.3.1 DRUG EFFECTIVENESS 113
11.3.2 SIDE EFFECTS 113
11.3.3 DOSAGE 113
11.4 ACADEMIC AND RESEARCH INSTITUTES 113
11.4.1 DRUG EFFECTIVENESS 114
11.4.2 SIDE EFFECTS 114
11.4.3 DOSAGE 114
11.5 OTHERS 114
12 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL 116
12.1 OVERVIEW 117
12.2 DIRECT TENDER 120
12.3 THIRD PARTY DISTRIBUTION 120
12.4 HOSPITAL PHARMACY 121
12.5 OTHERS 121
13 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION 123
13.1 NORTH AMERICA 124
13.1.1 U.S. 136
13.1.2 CANADA 143
13.1.3 MEXICO 150
14 NORTH AMERICA PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE 157
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 157
15 SWOT ANALYSIS 158
16 COMPANY PROFILE 159
16.1 THERMO FISHER SCIENTIFIC INC. 159
16.1.1 COMPANY SNAPSHOT 159
16.1.2 RECENT FINANCIALS 159
16.1.3 COMPANY SHARE ANALYSIS 160
16.1.4 PRODUCT PORTFOLIO 160
16.1.5 RECENT DEVELOPMENT 161
16.2 ILLUMINA, INC. 162
16.2.1 COMPANY SNAPSHOT 162
16.2.2 REVENUE ANALYSIS 162
16.2.3 COMPANY SHARE ANALYSIS 163
16.2.4 PRODUCT PORTFOLIO 163
16.2.5 RECENT DEVELOPMENTS 164
16.3 MYRIAD GENETICS, INC. 166
16.3.1 COMPANY SNAPSHOT 166
16.3.2 COMPANY SHARE ANALYSIS 166
16.3.3 PRODUCT PORTFOLIO 167
16.3.4 RECENT DEVELOPMENT 167
16.4 SONIC HEALTHCARE LIMITED 168
16.4.1 COMPANY SNAPSHOT 168
16.4.2 REVENUE ANALYSIS 168
16.4.3 COMPANY SHARE ANALYSIS 169
16.4.4 PRODUCT PORTFOLIO 169
16.4.5 RECENT DEVELOPMENTS 169
16.5 QIAGEN 170
16.5.1 COMPANY SNAPSHOT 170
16.5.2 RECENT FINANCIALS 170
16.5.3 COMPANY SHARE ANALYSIS 171
16.5.4 PRODUCT PORTFOLIO 171
16.5.5 RECENT DEVELOPMENTS 172
16.6 EUROFINS SCIENTIFIC 173
16.6.1 COMPANY SNAPSHOT 173
16.6.2 REVENUE ANALYSIS 173
16.6.3 PRODUCT PORTFOLIO 174
16.6.4 RECENT DEVELOPMENT 174
16.7 AB-BIOTICS, S.A. 175
16.7.1 COMPANY SNAPSHOT 175
16.7.2 PRODUCT PORTFOLIO 175
16.7.3 RECENT DEVELOPMENTS 175
16.8 BIOGENIQ INC. 177
16.8.1 COMPANY SNAPSHOT 177
16.8.2 PRODUCT PORTFOLIO 177
16.8.3 RECENT DEVELOPMENT 177
16.9 CASTLE BIOSCIENCE, INC. 178
16.9.1 COMPANY SNAPSHOT 178
16.9.2 REVENUE ANALYSIS 178
16.9.3 PRODUCT PORTFOLIO 179
16.9.4 RECENT DEVELOPMENT 179
16.10 CNSDOSE 180
16.10.1 COMPANY SNAPSHOT 180
16.10.2 PRODUCT PORTFOLIO 180
16.10.3 RECENT DEVELOPMENT 180
16.11 COLOR HEALTH, INC. 181
16.11.1 COMPANY SNAPSHOT 181
16.11.2 PRODUCT PORTFOLIO 181
16.11.3 RECENT DEVELOPMENTS 182
16.12 CORIELL LIFE SCIENCES 183
16.12.1 COMPANY SNAPSHOT 183
16.12.2 PRODUCT PORTFOLIO 183
16.12.3 RECENT DEVELOPMENTS 183
16.13 DYNAMIC DNA LABORATORIES 186
16.13.1 COMPANY SNAPSHOT 186
16.13.2 PRODUCT PORTFOLIO 186
16.13.3 RECENT DEVELOPMENTS 186
16.14 GENELEX (SUBSIADIARY OF INVITAE CORPORATION.) 188
16.14.1 COMPANY SNAPSHOT 188
16.14.2 REVENUE ANALYSIS 188
16.14.3 PRODUCT PORTFOLIO 189
16.14.4 RECENT DEVELOPMENT 189
16.15 GENEWIZ (PART OF AZENTA LIFE SCIENCES) 190
16.15.1 COMPANY SNAPSHOT 190
16.15.2 REVENUE ANALYSIS 190
16.15.3 PRODUCT PORTFOLIO 191
16.15.4 RECENT DEVELOPMENTS 191
16.16 GENOMIND, INC. 192
16.16.1 COMPANY SNAPSHOT 192
16.16.2 PRODUCT PORTFOLIO 192
16.16.3 RECENT DEVELOPMENTS 192
16.17 GENXYS 194
16.17.1 COMPANY SNAPSHOT 194
16.17.2 PRODUCT PORTFOLIO 194
16.17.3 RECENT DEVELOPMENTS 194
16.18 HEALTHSPEK 196
16.18.1 COMPANY SNAPSHOT 196
16.18.2 PRODUCT PORTFOLIO 196
16.18.3 RECENT DEVELOPMENTS 196
16.19 HUDSONALPHA 197
16.19.1 COMPANY SNAPSHOT 197
16.19.2 PRODUCT PORTFOLIO 197
16.19.3 RECENT DEVELOPMENT 197
16.20 MD LABS 198
16.20.1 COMPANY SNAPSHOT 198
16.20.2 PRODUCT PORTFOLIO 198
16.20.3 RECENT DEVELOPMENTS 198
16.21 MYDNA LIFE AUSTRALIA PTY LTD. 199
16.21.1 COMPANY SNAPSHOT 199
16.21.2 PRODUCT PORTFOLIO 199
16.21.3 RECENT DEVELOPMENT 199
16.22 ONEOME, LLC 200
16.22.1 COMPANY SNAPSHOT 200
16.22.2 PRODUCT PORTFOLIO 200
16.22.3 RECENT DEVELOPMENTS 200

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.